Mitsubishi Gas Chemical, Cirena partner for exclusive long-chain RNA distribution in Japan

This advanced technology enables the efficient chemical synthesis of RNA strands extending beyond 300 bases

Mitsubishi Gas Chemical Company (MGC) announced that it has reached a basic agreement with Cirena to begin negotiations for an exclusive distribution contract in Japan for products based on Cirena’s proprietary long-chain RNA synthesis technology. This advanced technology enables the efficient chemical synthesis of RNA strands extending beyond 300 bases, offering significant potential in the rapidly growing field of gene editing.

Under its Medium-Term Management Plan, “Grow UP 2026,” MGC has positioned the creation of new value through innovation as a key initiative to strengthen its business portfolio. Within this framework, MGC has identified the medical and food sectors as strategic focus areas. Recognizing the nucleic acid field as one of the most dynamic segments in the pharmaceutical industry, MGC has been actively expanding its presence through strategic collaborations. In July 2024, the company entered into a partnership with Hokkaido System Science Co. (HSS) to explore opportunities in the Contract Development and Manufacturing Organization (CDMO) business for nucleic acid-based pharmaceuticals.

This new collaboration with Cirena further strengthens MGC’s initiatives in the nucleic acid field. Cirena, established in October 2024, specializes in the synthesis of long-chain RNA using its proprietary synthetic chemistry platform and is currently focused on business development in the United States. The partnership stems from a shared vision: Cirena’s goal to expand the global application of its RNA synthesis technology aligns with MGC’s strategy to secure promising technologies that support its growth in the nucleic acid pharmaceutical CDMO business.

While the exclusive distribution agreement currently under negotiation will apply solely to the Japanese market, MGC and Cirena also plan to collaborate on marketing activities in regions outside the United States and Japan.

Guided by its corporate mission, “Creating Value to Share with Society,” MGC remains dedicated to contributing to a health-focused future by promoting the social implementation of innovative technologies. Through collaborations with partners such as Cirena and HSS, MGC aims to advance meaningful progress in the medical and food industries.